The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Nanodrugs: pharmacokinetics and safety
Open accessAbstract
To date, various nanodrug systems have been developed for different routes of administration, which include dendrimers, nanocrystals, emulsions, liposomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles. Nanodrug systems have been employed to improve the efficacy, safety, physicochemical properties, and pharmacokinetic/pharmacodynamic profile of pharmaceutical substances. In particular, functionalized nanodrug systems can offer enhanced bioavailability of orally taken drugs, prolonged half-life of injected drugs (by reducing immunogenicity), and targeted delivery to specific tissues. Thus, nanodrug systems might lower the frequency of administration while providing maximized pharmacological effects and minimized systemic side effects, possibly leading to better therapeutic compliance and clinical outcomes. In spite of these attractive pharmacokinetic advantages, recent attention has been drawn to the toxic potential of nanodrugs since they often exhibit in vitro and in vivo cytotoxicity, oxidative stress, inflammation, and genotoxicity. A better understanding of the pharmacokinetic and safety characteristics of nanodrugs and the limitations of each delivery option is necessary for the further development of efficacious nanodrugs with high therapeutic potential and a wide safety margin. This review highlights the recent progress in nanodrug system development, with a focus on the pharmacokinetic advantages and safety challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxic potential of materials at the nanolevel
Nel, A., Xia, T., Mädler, L., & Li, N. (2006) · Science · doi:10.1126/science.1114397 · Cited by 9,324
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Drug delivery and nanoparticles: Applications and hazards
de Jong (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s596 · Cited by 3,848
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Polymer-based nanocapsules for drug delivery
Mora-Huertas, C. E., Fessi, H., & Elaissari, A. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.10.018 · Cited by 1,742
Yin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452
Nanoparticles as drug delivery systems
Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70901-5 · Cited by 1,445
Solubilizing Excipients in Oral and Injectable Formulations
Strickley, R. G. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016235.32639.23 · Cited by 1,415
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach
des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., & Préat, V. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.013 · Cited by 1,305
Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., & Onoue, S. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.032 · Cited by 1,181
Self-citationHrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107
Nanoparticulate systems for brain delivery of drugs
Kreuter, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.015 · Cited by 958
Maeda, H., Sawa, T., & Konno, T. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00309-1 · Cited by 925
The degree and kind of agglomeration affect carbon nanotube cytotoxicity
WICK, P., MANSER, P., LIMBACH, L., DETTLAFFWEGLIKOWSKA, U., KRUMEICH, F., ROTH, S., STARK, W., & BRUININK, A. (2007) · Toxicology Letters · doi:10.1016/j.toxlet.2006.08.019 · Cited by 818
Biocompatibility of engineered nanoparticles for drug delivery
Naahidi, S., Jafari, M., Edalat, F., Raymond, K., Khademhosseini, A., & Chen, P. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.013 · Cited by 809
Shegokar, R., & Müller, R. H. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.044 · Cited by 740
Inhaled nanoparticles—A current review
Yang, W., Peters, J. I., & Williams, R. O. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.02.011 · Cited by 666
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Nanotechnology Safety Concerns Revisited
Stern, S. T., & McNeil, S. E. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfm169 · Cited by 560
Jinno, J.-I., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G. G., Higaki, K., & Kimura, T. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.11.013 · Cited by 510
Production methods for nanodrug particles using the bottom-up approach
Chan, H.-K., & Kwok, P. C. L. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.03.011 · Cited by 451
Kabanov, A. V., & Alakhov, V. Y. (2002) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v19.i1.10 · Cited by 447
Designing dendrimers for drug delivery
Liu, M., & Fréchet, J. M. J. (1999) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(99)00203-5 · Cited by 434
Martins, S., Sarmento, B. F. C. C., Ferreira, D., & Souto, E. B. (2007) · PubMed Central · Cited by 399
Nanotoxicology and nanoparticle safety in biomedical designs
Biazar, E., Majdi, Zafari, M., Avar, M., Aminifard, S., Zaeifi, D., Ai, Jafarpour, Montazeri, & Gh (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s16603 · Cited by 389
Manjunath, K., & Venkateswarlu, V. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.006 · Cited by 380
Nanoparticles for Biomedical Imaging: Fundamentals of Clinical Translation
Choi, H. S., & Frangioni, J. V. (2010) · Molecular Imaging · doi:10.2310/7290.2010.00031 · Cited by 351
Drug nanocrystals: in vivo performances.
Gao, L., Liu, G., Ma, J., Wang, X., Zhou, L., & Li, X. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.013 · Cited by 347
Clinical toxicities of nanocarrier systems.
Vega-Villa, K. R., Takemoto, J. K., Yáñez, J. A., Remsberg, C. M., Forrest, M. L., & Davies, N. M. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.007 · Cited by 325
Roger, E., Lagarce, F., Garcion, E., & Benoit, J.-P. (2010) · Nanomedicine · doi:10.2217/nnm.09.110 · Cited by 324
Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin
Zhang, N., Ping, Q., Huang, G., Xu, W., Cheng, Y., & Han, X. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.07.026 · Cited by 286
Sharma, A., Sharma, S., & Khuller, G. K. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh411 · Cited by 251
Polymeric hydrogels for oral insulin delivery
Chaturvedi, K., Ganguly, K., Nadagouda, M. N., & Aminabhavi, T. M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.005 · Cited by 244
Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9709-2 · Cited by 237
Role of Nanotechnology in Pharmaceutical Product Development
Devalapally, H., Chakilam, A., & Amiji, M. M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20875 · Cited by 230
Thomas, N., Holm, R., Müllertz, A., & Rades, T. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.027 · Cited by 215
Onoue, S., Takahashi, H., Kawabata, Y., Seto, Y., Hatanaka, J., Timmermann, B., & Yamada, S. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21964 · Cited by 206
Self-citationHANAFY, A., SPAHNLANGGUTH, H., VERGNAULT, G., GRENIER, P., TUBICGROZDANIS, M., LENHARDT, T., & LANGGUTH, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.005 · Cited by 203
Nano-encapsulation of azole antifungals: Potential applications to improve oral drug delivery
Pandey, R., Ahmad, Z., Sharma, S., & Khuller, G. K. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.05.027 · Cited by 192
Asthana, A., Chauhan, A. S., Diwan, P. V., & Jain, N. K. (2005) · AAPS PharmSciTech · doi:10.1208/pt060367 · Cited by 190
Kaminskas, L. M., McLeod, V. M., Kelly, B. D., Sberna, G., Boyd, B. J., Williamson, M., Owen, D. J., & Porter, C. J. H. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.05.013 · Cited by 176
In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors
Jain, A., & Jain, S. K. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.08.008 · Cited by 169
Liposomes and nanotechnology in drug development: focus on ocular targets
Honda, M., Asai, Oku, Araki, Tanaka, & Ebihara (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s30725 · Cited by 165
Morgen, M. M., Bloom, C., Beyerinck, R., Bello, A., Song, W., Wilkinson, K. F., Steenwyk, R. C., & Shamblin, S. L. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0558-7 · Cited by 147
Thomas, N., Holm, R., Garmer, M., Karlsson, J. J., Müllertz, A., & Rades, T. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9433-7 · Cited by 144
Formulation and Evaluation of Lidocaine Lipid Nanosystems for Dermal Delivery
Pathak, P. O., & Nagarsenker, M. S. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9287-1 · Cited by 137
Reddy, L. H., Sharma, R. K., Chuttani, K., Mishra, A. K., & Murthy, R. R. (2004) · The AAPS Journal · doi:10.1208/aapsj060323 · Cited by 135
Targeting the lymphatics using dendritic polymers (dendrimers)
Kaminskas, L. M., & Porter, C. J. H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.05.016 · Cited by 133
Watanabe, M., Kawano, K., Yokoyama, M., Opanasopit, P., Okano, T., & Maitani, Y. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.030 · Cited by 128
Effect of Crystal Size on the In Vitro Dissolution and Oral Absorption of Nitrendipine in Rats
Xia, D., Cui, F., Piao, H., Cun, D., Piao, H., Jiang, Y., Ouyang, M., & Quan, P. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0200-0 · Cited by 120
Fanciullino, R., Ciccolini, J., & Milano, G. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.010 · Cited by 115
Pharmacokinetics of paclitaxel-containing liposomes in rats
Fetterly, G. J., & Straubinger, R. M. (2003) · AAPS PharmSci · doi:10.1208/ps050432 · Cited by 108
Prajapati, R. N., Tekade, R. K., Gupta, U. D., et al. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002489 · Cited by 104
Feldman, E. J., Kolitz, J. E., Trang, J. M., Liboiron, B. D., Swenson, C. E., Chiarella, M. T., Mayer, L. D., Louie, A. C., & Lancet, J. E. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.07.006 · Cited by 100
Larsen, A. T., Ohlsson, A. G., Polentarutti, B. I., Barker, R. A., Phillips, A. R., Abu-Rmaileh, R., Dickinson, P. A., Abrahamsson, B., Østergaard, J., & Müllertz, A. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.11.004 · Cited by 98
Liu, W., Yang, X., & Ho, W. S. W. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22272 · Cited by 96
Reddy, L. H., & Murthy, R. S. R. (2004) · Biomedical Papers · doi:10.5507/bp.2004.029 · Cited by 93
Molecular and magnetic resonance imaging: The value of immunoliposomes
Kozlowska, D., Foran, P., MacMahon, P. J., Shelly, M. J., Eustace, S. J., & O’Kennedy, R. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.09.003 · Cited by 89
A Novel Solid-in-oil Nanosuspension for Transdermal Delivery of Diclofenac Sodium
Piao, H., Kamiya, N., Hirata, A., Fujii, T., & Goto, M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9445-7 · Cited by 88
Exploiting the Vitamin B12 Pathway To Enhance Oral Drug Delivery via Polymeric Micelles
Francis, M. F., Cristea, M., & Winnik, F. M. (2005) · Biomacromolecules · doi:10.1021/bm0503165 · Cited by 86
Micellar solutions of triblock copolymer surfactants with pilocarpine
Pepić, I., Jalšenjak, N., & Jalšenjak, I. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.11.032 · Cited by 84
Shahbazi, M., & Santos, H. A. (2012) · Current Drug Metabolism · doi:10.2174/138920013804545133 · Cited by 82
Onoue, S., Uchida, A., Kuriyama, K., et al. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.03.015 · Cited by 82
Self-citationJia, L., Wong, H., Wang, Y., Garza, M., & Weitman, S. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10272 · Cited by 80
Kawabata, Y., Yamamoto, K., Debari, K., Onoue, S., & Yamada, S. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.12.009 · Cited by 78
Self-citationChuang, E., Lin, K., Su, F.-Y., Chen, H., Maiti, B., Ho, Y., Yen, T., Panda, N., & Sung, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.011 · Cited by 74
Methods used to assess pulmonary deposition and absorption of drugs
Mobley, C., & Hochhaus, G. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01691-9 · Cited by 72
Influence of dendrimers on red blood cells
Ziemba, B., Matuszko, G., Bryszewska, M. J., & Klajnert‐Maculewicz, B. (2011) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-011-0033-9 · Cited by 70
Nanonization of megestrol acetate by laser fragmentation in aqueous milieu
Sylvestre, J., Tang, M.-C., Fürtös, A., Leclair, G., Meunier, M., & Leroux, J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.034 · Cited by 70
Onoue, S., Nakamura, T., Uchida, A., Ogawa, K., Yuminoki, K., Hashimoto, N., Hiza, A., Tsukaguchi, Y., Asakawa, T., Kan, T., et al. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.05.014 · Cited by 69
Self-citationKaminskas, L. M., Kelly, B. D., McLeod, V. M., Sberna, G., Boyd, B. J., Owen, D. J., & Porter, C. J. H. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1001872 · Cited by 64
Lactoferrin-Conjugated Dendritic Nanoconstructs for Lung Targeting of Methotrexate
Kurmi, B. D., Gajbhiye, V., Kayat, J., & Jain, N. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22469 · Cited by 61
Inhalative nanomedicine—Opportunities and challenges
Bur, M., Henning, A., Hein, S., Schneider, M., & Lehr, C. (2009) · Inhalation Toxicology · doi:10.1080/08958370902962283 · Cited by 59
Lipid Formulation as a Drug Carrier for Drug Delivery
Tomii, Y. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023395871 · Cited by 56
Nanotoxicology for Safe and Sustainable Nanotechnology
Drobne, D. (2007) · Archives of Industrial Hygiene and Toxicology · doi:10.2478/v10004-007-0040-4 · Cited by 53
Nanomedicines and Nanodiagnostics Come of Age
Uchegbu, I. F., & Siew, A. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23377 · Cited by 48
Onoue, S., Kojo, Y., Suzuki, H., Yuminoki, K., Kou, K., Kawabata, Y., Yamauchi, Y., Hashimoto, N., & Yamada, S. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.05.022 · Cited by 45
Self-citationOnoue, S., Aoki, Y., Kawabata, Y., et al. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22299 · Cited by 44
Self-citationMori, S., Matsuura, A., Prasad, Y. V. R., & Takada, K. (2004) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.27.418 · Cited by 35
Ternary Polymeric Nanoparticles for Oral siRNA Delivery
Zhang, J., He, C., Tang, C., & Yin, C. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0961-8 · Cited by 31
Kawakami, S., Yamamura, K., Mukai, T., et al. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011776423 · Cited by 28
Manvelian, G. Z., Daniels, S., & Gibofsky, A. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2524 · Cited by 28
Teshima, M., Fumoto, S., Nishida, K., et al. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.03.004 · Cited by 25
Manvelian, G. Z., Daniels, S., & Altman, R. D. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2580 · Cited by 22
Onoue, S., Kuriyama, K., Uchida, A., Mizumoto, T., & Yamada, S. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0379-8 · Cited by 19
Self-citation
Cited by
Applications of nanoparticle systems in drug delivery technology
Rizvi, S. A. A., & Saleh, A. M. (2018) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.10.012 · Cited by 1,334
Safe Nanoparticles: Are We There Yet?
Najahi-Missaoui, W., Arnold, R. D., & Cummings, B. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010385 · Cited by 581
Wen, H., Jung, H., & Li, X. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9814-9 · Cited by 574
Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications
Kannan, R. M., Nance, E., Kannan, S., & Tomalia, D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12280 · Cited by 542
Choi, Y. H., & Han, H.-K. (2018) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0370-4 · Cited by 406
Metadata
- Authors
- Onoue, S., Yamada, S., & Chan, K.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2014-02
- Volume
- 9
- Pages
- 1025
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2066936530
- Cited by
- 382
- References
- 88
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.